Related Experiment Video

Updated: Aug 7, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

The natural history of corticosteroid therapy for ulcerative colitis in children

Jeffrey Hyams1, James Markowitz, Trudy Lerer

  • 1Connecticut Children's Medical Center, Hartford, Connecticut, USA. jhyams@ccmckids.org

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|July 6, 2006
PubMed

Insights

Corticosteroid therapy shows excellent short-term results for pediatric ulcerative colitis (UC). However, nearly half of young patients develop corticosteroid dependence, even with immunomodulator use.

Area of Science:

  • Pediatric Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Outcomes

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting children.
  • Corticosteroid therapy is a common initial treatment for pediatric UC.
  • Understanding long-term outcomes of corticosteroid use in this population is crucial.

Purpose of the Study:

  • To determine the clinical outcomes of corticosteroid therapy in children newly diagnosed with ulcerative colitis.
  • To evaluate the rates of corticosteroid responsiveness, dependence, and refractory disease.
  • To assess colectomy rates and the use of immunomodulators.

Main Methods:

  • Prospective data collection from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry.
  • Inclusion of children under 16 years newly diagnosed with UC.
  • Classification of patients into corticosteroid responsive, dependent, or refractory groups based on outcomes at 3 months and 1 year.

Main Results:

  • 77% of 97 pediatric UC patients received corticosteroids, with 62 treated early.
  • Early corticosteroid treatment led to inactive or mild disease in 87% at 3 months.
  • At 1 year, 50% were corticosteroid responsive, while 45% were corticosteroid dependent; 5% required colectomy.

Conclusions:

  • Corticosteroids provide excellent short-term symptom control in pediatric ulcerative colitis.
  • A significant proportion (45%) of children develop corticosteroid dependence despite immunomodulator use.
  • Further research into optimizing long-term management strategies for pediatric UC is warranted.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...